Evidence map›Paper›PMID 38625415›Full record

ArticleBlood research2024

Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A: correlation with "Inhibitor" formation.

Omid Reza Zekavat, Yasaman Movahednezhad, Amin Shahsavani, Sezaneh Haghpanah, Negin Shokrgozar, Hossein Golmoghaddam, Mehdi Kalani, Mohammad Reza Bordbar, Nargess Arandi

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Omid Reza ZekavatHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Yasaman MovahednezhadHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Amin ShahsavaniHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Sezaneh HaghpanahHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Negin ShokrgozarHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hossein GolmoghaddamDepartment of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Mehdi KalaniDepartment of Immunology, Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Reza BordbarHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Nargess ArandiHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. arandin@sums.ac.ir.ORCID http://orcid.org/0000-0001-6489-0979
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDevelopment of antibodies against infused Factor VIII (FVIII) or "inhibitors" represents a major challenge following FVIII replacement therapy in patients with hemophilia A (HA). Recent studies have shown that certain cellular compartments of the immune system contribute to the production of such antibodies. Herein, we determined the frequency of class-switched CD19

methodsThis cross-sectional case-control study enrolled 32 patients with severe HA, including 8 with and 24 without inhibitors, and 24 healthy individuals. The frequencies of the memory B cell subsets and plasmablasts were determined using flow cytometry.

resultsThe frequency of CD19

conclusionThis study is the first to demonstrate a dysregulated proportion of CD19

Indexed as

InhibitorsMemory B cellsPlasmablastsSevere hemophilia A

Identifiers

PMID38625415
PMCPMC11021380
OpenAlexW4394832311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.